HOME >> MEDICINE >> NEWS
Fever of unknown origin: a marker for occult cancer?

EMBARGO: 00:01H (London time) Wednesday September 28, 2005. In North America the embargo lifts at 6:30pm ET Tuesday September 27, 2005. FEVER OF UNKNOWN ORIGIN: A MARKER FOR OCCULT CANCER? Fever of unknown origin might be a marker of occult cancer, according to research published online today by THE LANCET ONCOLOGY.

Fever of unknown origin is characterised by a fever of more than 3 weeks duration, temperatures of more than 38.3C and a failure to identify the origin of the fever. Underlying causes of these fevers are difficult to diagnose, but proposed causes are infections, cancers and collagen-vascular diseases. Henrik Toft Sorensen and colleagues hypothesised that patients with fever of unknown origin might have a higher risk of cancer than the general population.

To test their theory, they assessed 43 205 patients discharged for the first time from Danish hospitals after treatment for fever of unknown origin from 1977-98. Using registry data, they examined whether these patients had a higher risk of subsequent cancer than that expected based on cancer incidence in the general population. They also compared survival of these patients with cancer patients without fever, but matched for cancer site, age at diagnosis of cancer and year of cancer diagnosis.

Within the first year of follow-up after discharge from hospital, patients with fever had an increased risk of developing cancer and 399 cancers were diagnosed (standardised incidence ratio 2.3 [95%CI 2.1-2.5]). This risk was highest for haematological cancers and sarcomas and, although reduced, the overall increased risk remained after 1 year of follow-up. Some cancer patients with fever also had a worse prognosis than did the controls without fever (mortality ratio 1.4 [1.2-1.6]).

Prof Sorensen states "Heightened diagnostic effort could account for some of the association; however, after several years of follow-up, diagnostic bias should not be a major contributing
'"/>

Contact: Joe Santangelo
j.santangelo@elsevier.com
+1-212-633-3810
Lancet
27-Sep-2005


Page: 1 2

Related medicine news :

1. Yellow Fever
2. Benefits of testosterone treatment unknown, research shows
3. The unknown risks of arthritis
4. Daycare illness guidelines exist, but largely unknown
5. Depression linked to previously unknown dopamine regulator
6. Novel candidate biomarker for heart failure also strongly predicts risk of death
7. USC researchers show that molecular markers predict tumor recurrence
8. OHSU Cancer Institute researcher identifies protein marker for prostate cancer survival
9. Advances in screening and markers improve early detection of colorectal cancer
10. Genetic marker linked to aggressive prostate cancer
11. Genetic markers in surrounding tissues linked to breast cancer tumor grade, presence of metastases

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Fever unknown origin marker for occult cancer

(Date:3/28/2015)... Rocket Pure , a manufacturer of natural body ... new natural sunscreen. They are offering the sunscreen in ... come with a bonus lip balm sunscreen. , The new ... Click to see the natural sunscreen on Amazon . ... made with non-nano zinc oxide and provides broad-based protection against ...
(Date:3/28/2015)... With more than 4,500 scientists, clinicians and ... and musculoskeletal diseases gathered here for the World ... time in the 17-year history of the field’s ... is an emerging non-pharmaceutical protocol for enhancing bone ... Wolff’s law, osteogenic loading at multiples of body ...
(Date:3/28/2015)... (PRWEB) March 28, 2015 An article ... problem which could prove critical to organizations that deal ... a critical aspect of data security, is worsening . ... data security report, every major category out of the ... penetration testing. “With all the craziness that has gone ...
(Date:3/28/2015)... 28, 2015 Delaying rotator cuff surgery ... according to research presented today at the American Orthopaedic ... , “Our study compared results for 170 patients who ... additional glenohumeral joint capsule release procedure to relieve stiffness ... PhD, lead author from St. George Hospital in Sydney, ...
(Date:3/28/2015)... Omaha, NE (PRWEB) March 28, 2015 ... leader in healthcare staffing, including physical therapy jobs, ... exhibitor at the Ohio Physical Therapy Association Annual ... the Renaissance Columbus Downtown Hotel in Columbus, OH. ... programming, networking opportunities, and exhibits with products and ...
Breaking Medicine News(10 mins):Health News:Rocket Pure Releases New Natural Sunscreens For Athletes 2Health News:Rocket Pure Releases New Natural Sunscreens For Athletes 3Health News:Non-Drug Protocol for Building Bone Density Expected to Steal Spotlight at World Congress on Osteoporosis 2Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 2Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 3Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 4Health News:No Need to Delay Rotator Cuff Surgery, Study Shows 2Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the Ohio Physical Therapy Association Annual Conference 2
(Date:3/27/2015)... , March 27, 2015   Hospira, Inc. ... in biosimilars and the world,s leading provider of ... that support an evaluation of biosimilarity of its ... and Drug Administration (FDA) conditionally approved name of ... (epoetin alfa). These study data were presented at ...
(Date:3/27/2015)... NEW YORK , March 27, 2015 /PRNewswire/ ... specialty pharmaceutical and medical device company focused on ... primary and metastatic liver cancers, announces the reporting ... the Company,s Melphalan Hydrochloride for Injection with the ... therapies in a poster presentation at the Society of ...
(Date:3/26/2015)... March 26, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ... a focus on Omega-3 therapies for cardiovascular disease and ... issued 763,752 common shares of the Corporation (the "Common ... the period of December 5 th , 2014 to ... Notes that is due on or before April 1, ...
Breaking Medicine Technology:Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 2Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 3Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 2Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 3Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 4Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 5Pivotal Therapeutics announces payment of interest on outstanding convertible notes 2
Cached News: